Toll Free: 1-888-928-9744

Kowa Company, Ltd. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 46 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Kowa Company, Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Kowa Company, Ltd. - Product Pipeline Review - 2014', provides an overview of the Kowa Company, Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Kowa Company, Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Kowa Company, Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Kowa Company, Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Kowa Company, Ltd.'s pipeline products

Reasons to buy

- Evaluate Kowa Company, Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Kowa Company, Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Kowa Company, Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Kowa Company, Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Kowa Company, Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Kowa Company, Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Kowa Company, Ltd. Snapshot 5
Kowa Company, Ltd. Overview 5
Key Information 5
Key Facts 5
Kowa Company, Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Kowa Company, Ltd. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Kowa Company, Ltd. - Pipeline Products Glance 13
Kowa Company, Ltd. - Late Stage Pipeline Products 13
Pre-Registration Products/Combination Treatment Modalities 13
Phase III Products/Combination Treatment Modalities 14
Kowa Company, Ltd. - Clinical Stage Pipeline Products 15
Phase II Products/Combination Treatment Modalities 15
Phase I Products/Combination Treatment Modalities 16
Kowa Company, Ltd. - Early Stage Pipeline Products 17
Preclinical Products/Combination Treatment Modalities 17
Discovery Products/Combination Treatment Modalities 18
Kowa Company, Ltd. - Drug Profiles 19
ripasudil 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
K-103IP 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
K-877 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
peretinoin 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
anagliptin 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
K-134 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
K-828-AB 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
pitavastatin CR 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
epirubicin hydrochloride 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
K-312 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Acyl-Coenzyme A Inhibitor 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
K-163SZ 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Kowa Company, Ltd. - Pipeline Analysis 33
Kowa Company, Ltd. - Pipeline Products by Target 33
Kowa Company, Ltd. - Pipeline Products by Route of Administration 35
Kowa Company, Ltd. - Pipeline Products by Molecule Type 36
Kowa Company, Ltd. - Pipeline Products by Mechanism of Action 37
Kowa Company, Ltd. - Recent Pipeline Updates 39
Kowa Company, Ltd. - Dormant Projects 42
Kowa Company, Ltd. - Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46
List of Tables
Kowa Company, Ltd., Key Information 5
Kowa Company, Ltd., Key Facts 5
Kowa Company, Ltd. - Pipeline by Indication, 2014 8
Kowa Company, Ltd. - Pipeline by Stage of Development, 2014 9
Kowa Company, Ltd. - Monotherapy Products in Pipeline, 2014 10
Kowa Company, Ltd. - Partnered Products in Pipeline, 2014 11
Kowa Company, Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 12
Kowa Company, Ltd. - Pre-Registration, 2014 13
Kowa Company, Ltd. - Phase III, 2014 14
Kowa Company, Ltd. - Phase II, 2014 15
Kowa Company, Ltd. - Phase I, 2014 16
Kowa Company, Ltd. - Preclinical, 2014 17
Kowa Company, Ltd. - Discovery, 2014 18
Kowa Company, Ltd. - Pipeline by Target, 2014 34
Kowa Company, Ltd. - Pipeline by Route of Administration, 2014 35
Kowa Company, Ltd. - Pipeline by Molecule Type, 2014 36
Kowa Company, Ltd. - Pipeline Products by Mechanism of Action, 2014 38
Kowa Company, Ltd. - Recent Pipeline Updates, 2014 39
Kowa Company, Ltd. - Dormant Developmental Projects,2014 42
Kowa Company, Ltd., Other Locations 43
Kowa Company, Ltd., Subsidiaries 43 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify